BOSTON, MA -- (Marketwired) -- 11/08/17 -- Real world evidence is poised to play a growing…
Continue ReadingTag: tufts
Cardiovascular Drug Approval Rate in the U.S. Fell as Development Time Rose, According to the Tufts Center for the Study of Drug Development
BOSTON, MA -- (Marketwired) -- 09/12/17 -- Although the rate at which investigational drugs received marketing…
Continue ReadingAbuse-Deterrent Opioid Development and Uptake Are Tied to Efficacy and Regulatory/Payer Policies, According to the Tufts Center for the Study of Drug Development
BOSTON, MA -- (Marketwired) -- 07/13/17 -- Although 10 new opioid products with abuse-deterrent formulations (ADF)…
Continue ReadingAccelerating Pace of Approvals and a Strong Development Pipeline Indicate Vigorous Growth for New Biotech Products, According to the Tufts Center for the Study of Drug Development
BOSTON, MA -- (Marketwired) -- 05/09/17 -- Biopharmaceuticals accounted for 35% of all new drug approvals…
Continue ReadingPoor Physician and Nurse Engagement Contributes to Low Patient Recruitment Rates, According to the Tufts Center for the Study of Drug Development
BOSTON, MA -- (Marketwired) -- 01/11/17 -- Although physicians and nurses are familiar with, and comfortable…
Continue ReadingCost to Develop and Win Marketing Approval for a New Drug Is $2.6 Billion, According to the Tufts Center for the Study of Drug Development
BOSTON, MA -- (Marketwired) -- 11/18/14 -- Developing a new prescription medicine that gains marketing approval,…
Continue ReadingADVISORY – Tufts CSDD to Disclose Cost of Developing a New Drug at Nov. 18 Briefing
BOSTON, MA -- (Marketwired) -- 11/10/14 --Tufts Center for the Study of Drug Development, Tufts University,…
Continue Reading